Scientists have figured out all the steps to make morphine and similar painkillers without using opium poppies, potentially opening the door for home-brewed drugs. Some experts are calling for regulations to prevent tinkerers from making morphine, which can be converted into heroin.
Pharmaceutical Processing sat down with Rockwell Automation’s Paula Puess and Khris...
Dyadic International, Inc. is a global biotechnology company focused on enzymes and other...
ANI Pharmaceuticals has acquired the approved new drug application ("NDA") for a testosterone gel 1% product previously licensed to Teva Pharmaceuticals.
Vitae Pharmaceuticals, a clinical-stage biotechnology company, recently provided financial results and pipeline reports for the first quarter of 2015.
Sigma-Aldrich Corporation's new facility will support commercial-scale gene therapy production, testing and filling.
Juno Therapeutics, a biopharmaceutical company focused on cancer treatment, announced today that it has acquired Stage Cell Therapeutics GmbH.
Inovio Pharmaceuticals announced that the company has initiated a phase I trial to evaluate the safety, tolerability and immune responses of their DNA immunotherapy for Ebola.
Endo International has acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas.
New analysis finds that the market could reach $13.4 billion in 2019, due in part to advanced diagnosis capabilities.
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing therapeutics for the treatment of cancer provided an update of its three clinical development programs.
BASF recently announced plans to sell several prominent pharmaceutical ingredients to Siegfried Holding AG for $306 million.
Bellicum Pharmaceuticals, Inc. today announced that it has entered into a lease agreement to enable in-house cell therapy manufacturing to supply clinical trials.
Ways to implement the manufacturing and prototyping technology within the pharmaceutical marketplace were highlighted at INTERPHEX 2015.
Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Q1 results.
Portola Pharmaceuticals today provided a corporate update and reported its financial results for the first quarter.
MorphoSys AG announced today that it has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V.
Eli Lilly and Company today announced plans to establish a new drug delivery and device innovation center in Cambridge, Massachusetts.
Alexion Pharmaceuticals will pay a huge premium to buy fellow rare disease treatment maker Synageva BioPharma in an $8.4-billion deal for a company with no products on the market.
Juno Therapeutics and Fate Therapeutics announced a strategic collaboration to identify and utilize small molecules to modulate Juno's genetically-engineered T cell product for potentially treating cancer patients.
The global market for Alzheimer’s Disease treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023.
Amyris, Inc., the industrial bioscience company, today announced financial results for the first quarter of 2015.
Pharmaceutical processors face a number of challenges in determining the direction they should take when considering internal investments – but a lack of options have never been amongst them.
While it’s a vital link between a facility and the pharmaceuticals shipped in and out every day, the loading dock presents the greatest opportunity for energy losses and damage to precious materials and products.
Shared service management is an important development in the collaboration between an organization’s supporting services, and can make an organization more Lean.
Downstream processing continues to impact capacity at the majority of biopharmaceutical manufacturing facilities.
Dow Development Laboratories in California is working to position itself as the "go-to" contract manufacturer for topical product development services.
The GMP commercial launch manufacturing facility in Cranbury will focus on antibody biosimilars.
- Page 1